DGAP-News: CureVac / Key word(s): Alliance/Agreement
CureVac : CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
07.01.2021 / 08:30
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
- Companies enter into a collaboration and services agreement
- Bayer to support CureVac in numerous areas, including development and supply of CVnCoV
- CureVac benefits from Bayer s expertise and established infrastructure
- Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany/ Boston, USA, January 7, 2021 -
Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its exper
Bayer, National Heart Center Singapore to develop explorative cardiovascular center
By Anh Nguyen December 22, 2020 | 04:43 pm GMT+7
Bayer and National Heart Center Singapore (NHCS) announced they had inked a five-year agreement to develop a “Center of Excellence for Explorative Cardiovascular Studies.”
The center aims to boost patient-centricity in research and development (R&D) and improve treatment outcomes in cardiovascular disease (CVD) management.
Combining NHCS’s vast experience in managing Asian CVD patients and clinical research with Bayer’s expertise in pharmaceutical R&D, the center will generate and integrate high quality patient data into early clinical research that would allow better understanding of the underlying biology of CVDs. Results could potentially lead to future targeted therapies to address unmet medical needs in defined patient populations. Bayer will contribute S$5.4 million ($4 million) towards the setup of the center.
Bayer and NHCS to set up Center of Excellence for Explorative Cardiovascular Studies vir.com.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vir.com.vn Daily Mail and Mail on Sunday newspapers.
Bayer and NHCS to set up Centre of Excellence for Explorative Cardiovascular Studies 17:03 | 18/12/2020
Bayer and National Heart Centre Singapore today announced that they have entered into a 5-year collaboration agreement to set up a Center of Excellence for Explorative Cardiovascular Studies.
Bayer and NHCS will collaborate on forming a better understanding of cardiovascular diseases in Asian patients. Photo: Freepik
Bayer and National Heart Centre Singapore (NHCS) will establish a Center of Excellence for Explorative Cardiovascular Studies with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease (CVD) management.
Combining NHCSâ vast experience in managing Asian CVD patients and clinical research and Bayerâs expertise in pharmaceutical R&D, the centre will generate and integrate high-quality patient data into early clinical research which will allow the b
E-Mail
Leveraging on Asian patient data, the 5-year collaboration aims to boost patientcentricity in R&D, leading to improved treatment outcomes in cardiovascular disease (CVD) management.
The Center will generate and integrate high quality patient data into early clinical research to inform future targeted therapies for CVDs.
Bayer will contribute S$5.4million (approx. EUR 3.4 million) towards this
collaboration.
Singapore, December 17, 2020 - Bayer and National Heart Centre Singapore (NHCS) today announced that they have entered into a 5-year collaboration agreement to set up Center of Excellence for Explorative Cardiovascular Studies (hereinafter Center ) with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease (CVD) management. Combining NHCS vast